Average Wholesale Price Fraud: How Manufacturers Marketed the Spread

Average wholesale price fraud uses false published drug prices to inflate reimbursement and sell the resulting profit to the pharmacies or medical practices buying the drugs. The seller offers one price to its customer and supplies a higher number for the payment calculation. The customer keeps the difference, and taxpayers fund the sales incentive. If you work in pricing, sales or pharmacy purchasing, you may know both numbers and what the customer was told about the money between them.

Who Profits From the Spread?

The pharmacy or medical practice buying the drug can profit from the difference between its acquisition cost and the reimbursement it receives. The manufacturer benefits when that margin persuades the customer to choose its product. Published average wholesale price connects the sales pitch to the payer’s money.

In the historical Medicare model, a physician practice bought a drug, administered it and billed Medicare. Payment followed a percentage of published AWP. The practice’s actual purchase price could be much lower, particularly after discounts. A manufacturer that could influence both the selling price and the published benchmark could influence what the practice earned from buying its drug.

Patients who paid coinsurance could also pay more when an inflated average wholesale price raised the allowed charge. The spread reached into the patient’s pocket as well as the public budget.

The pharmacy route puts another buyer in the same position. A pharmacy buys stock from a wholesaler or directly from a manufacturer, then receives payment when it dispenses the drug. When the reimbursement formula follows AWP, the published number helps determine the money coming in. The supplier’s actual price determines the money going out.

In PBM spread pricing, a pharmacy benefit manager keeps the difference between what it charges a drug plan and what it pays a pharmacy. In the manufacturer AWP cases, the seller allegedly used an inflated reimbursement benchmark to make its customer’s purchase more profitable.

How Is AWP Calculated?

Average wholesale price is a commercial publisher’s benchmark built from supplied pricing information. Its name does not mean that the publisher averaged the prices pharmacies actually paid.

The historical pricing model used a formulaic markup over wholesale acquisition cost. The court examining the AWP industry described standard markups of 20 or 25 percent. Those markups outlasted the wholesale margins they had once reflected. A fixed addition to a list price could keep producing a published benchmark after the underlying commercial relationship had changed.

Medi-Span’s pricing policy makes the distinction explicit. Wolters Kluwer says its published AWP does not represent actual wholesale transactions or the discounts and rebates offered to buyers. It relies on manufacturer pricing reports and does not independently investigate whether those reports match marketplace transactions.

For someone inside the business, this reporting chain matters as much as the invoice. The manufacturer knows the price it offers. The publisher receives the price submitted for publication. The payer uses the published benchmark in its calculation. The fraud allegations connect the number supplied at the beginning to the overpayment at the end.

When the Spread Became the Sales Pitch

Marketing the spread means selling a drug on the profit its reimbursement can leave the buyer. In the AWP cases, the government alleged that manufacturers inflated the published price and then used the resulting margin to induce purchases.

The HHS Inspector General’s May 2003 guidance explained why that arrangement mattered. A manufacturer controlling the spread could control its customer’s profit. Manipulating AWP to raise that profit moved the cost of the inducement onto government health care programs. The guidance identified sales representatives promoting the spread, or promising a particular profit in exchange for a purchase, as evidence of the seller’s purpose.

Dey’s respiratory-drug case put that sales model into a concrete civil resolution. In December 2010, the Justice Department announced a $280 million settlement with Dey. It alleged that Dey reported inflated drug prices and used the difference from actual selling prices to attract purchases through higher government reimbursement.

Ven-A-Care of the Florida Keys, a home-infusion company, and its principals brought the qui tam case. The Justice Department announced an approximately $67.2 million whistleblower reward. From the customer’s side, a buyer could compare the actual purchase with the reimbursement.

The sales conversation supplies something the price list alone cannot. It can connect the spread to the decision to buy. A customer-facing comparison of purchase cost and expected reimbursement, or an instruction to emphasize that profit, explains how the reported number became a competitive advantage. A supplier that refused to inflate its reported price could lose the sale to one offering a larger reimbursement windfall.

What Is the Difference Between AWP and WAC?

Average wholesale price is a published reimbursement benchmark, while wholesale acquisition cost is the manufacturer’s list price to wholesalers or direct purchasers, excluding discounts, rebates and other price reductions. A WAC figure therefore does not tell us the customer’s final acquisition cost either.

A comparison of AWP with WAC compares published pricing measures. To understand what the customer earned, we need the actual purchase price and the reimbursement. A discount or rebate can change the buyer’s cost without changing the list price appearing in a pricing guide.

What Is the Medicaid Best Price Rule?

The Medicaid Best Price rule uses the lowest qualifying manufacturer price, together with average manufacturer price, to determine the basic rebate on covered brand drugs. Hiding a qualifying discount can leave Best Price too high and the rebate owed to Medicaid too low, a different money path from inflating a pharmacy’s reimbursement.

ASP Follows Sales and Price Concessions

Average sales price is a sales-based measure used for most Medicare Part B drug payments, incorporating specified discounts, rebates, chargebacks and purchase-linked free goods. Omitting a qualifying discount, including a prompt-pay discount, can leave the reported price too high and preserve a reimbursement margin at the government’s expense.

What Happened to AWP?

Medicare moved most Part B drugs to average sales price in 2005, and Medicaid later moved toward actual acquisition cost. AWP nevertheless survived in narrower payment channels. The change in Medicare’s main payment formula left other reimbursement methods operating alongside it.

The acquisition-cost problem was visible well before the change. An HHS Inspector General report issued in 1997 measured generic acquisition prices averaging 42.5% below AWP. Its 2002 report, using later purchase data, measured 65.93% below AWP. These were comparisons with pharmacy purchase prices, the numbers the published benchmark was supposed to help estimate.

The Centers for Medicare & Medicaid Services described the competitive problem in 2003: actual market prices could fall with generic competition while published AWPs failed to fall by a corresponding amount. A cheaper drug could leave a larger reimbursement margin. Competition at the purchase counter did not automatically deliver the same saving to the government paying the claim.

Medicaid’s 2016 covered outpatient drug rule moved pharmacy payment toward actual acquisition cost plus a professional dispensing fee. The formula pairs ingredient cost with a separate payment for the work of dispensing. CMS explained that AWP and WAC could fail to represent purchase prices because they did not necessarily include the available discounts and concessions.

National Average Drug Acquisition Cost draws on voluntarily submitted invoices from a sample of retail community pharmacies.

Average wholesale price remained visible in CMS’s July 2026 Part B payment file, including vaccine and blood-product entries paid at 95% of AWP. The Medicare Payment Advisory Commission’s November 2025 payment guide also described AWP as a possible fallback when ASP data were unavailable. Federal workers’ compensation has used AWP-based pharmacy payment schedules as well.

How Wholesaler Markup Information Inflated AWP

AWP publisher markup information was central to the wholesaler fraud allegations against McKesson. The Justice Department alleged that McKesson supplied inflated markup percentages to First DataBank, which published the resulting AWP benchmarks used by Medicaid.

The April 2012 McKesson resolution included a $187 million settlement for the federal share of alleged Medicaid overpayments. The alleged pricing actor was a wholesaler. First DataBank was the publisher receiving its information.

That places another set of employees inside the mechanism. The person responsible for sending publisher data can know how the markup was chosen. The person handling commercial sales can know what customers actually paid. The payer sees the resulting published figure. Connecting those jobs can reveal how information about a supposed wholesale price became a government payment input.

The Same Pitch Reached Ordinary Drugs and Compounding Ingredients

The average wholesale price cases reached respiratory products, ordinary generics, infusion fluids and ingredients used by compounding pharmacies. Across those products, the recurring allegation was that a reported price created reimbursement well above the customer’s purchase cost.

The Justice Department’s December 2010 manufacturer settlements included Roxane, Abbott and B. Braun. Roxane allegedly reported inflated prices for furosemide, then marketed the reimbursement spread. Abbott’s allegations covered sterile water. B. Braun’s included infusion fluids.

Ven-A-Care was part of this group of cases too. A home-infusion business could recognize a discrepancy in products it understood and purchased. The product knowledge was commercial and practical: what the drug was, what it cost and how the healthcare program paid for it.

Fagron Put the Difference in Dollars Per Gram

Fagron’s November 2019 settlement concerned alleged inflation of ingredient AWPs and marketing the spread to compounding pharmacies. The government said its subsidiary Freedom Pharmaceuticals reported an AWP of $3,500 per gram for fluticasone propionate while typically selling it for about $160 per gram.

The settlement was $22.05 million and involved claims under TRICARE and federal workers’ compensation. The alleged sales advantage came from the reimbursement number, with the government financing the customer’s margin.

A Complaint Described the Instruction to Sales Staff

The government’s complaint against Professional Compounding Centers of America alleged that the instruction came from senior management. The Justice Department joined a case originally brought by a whistleblower and described the sales direction in its complaint:

The allegation connects pricing to a management instruction and then to the customer pitch. It gives an insider a recognizable business activity to discuss: what sales staff were told to emphasize when offering the ingredient.

Medisca Shows the Later Ingredient Case

In November 2024, Medisca agreed to a $21.75 million settlement over alleged inflated AWPs for resveratrol and mometasone furoate used by pharmacies billing TRICARE and federal workers’ compensation. A pharmacist brought the whistleblower case.

The buyer’s view remained important. An ingredient supplier set the reported price, while a pharmacy bought the ingredient and submitted the resulting prescription claim. The purchase and reimbursement sat on opposite sides of the same pharmacy business.

What the Settlement Study Found

Public Citizen’s Health Research Group found that overcharging state health programs, mainly Medicaid, was the most common violation behind state pharmaceutical settlements in its 2010 study. Its discussion identified inflated published AWPs as the principal form of that overcharging and described the consequence:

The study brings the cases back to the payment design. A published price could determine reimbursement even when the transaction underneath it cost far less. The financial attraction to the buyer and the cost to Medicaid were parts of the same arrangement.

What Evidence Is Needed to Prove Fraud?

Publisher submissions, purchase invoices and sales instructions can connect the reported benchmark to the actual price, the reimbursement and the decision to promote the difference.

We work through those connections with you. A pricing employee may understand the submission to the publisher. A sales representative may know why customers were shown reimbursement margins. A pharmacy buyer may know the discount and the payment received. Together, those details can explain how the company made a product attractive with money coming from a government program.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. The Dey and ingredient cases show why knowledge from the buying side can matter alongside knowledge from inside the supplier.

When the Spread Was Part of Your Job

If you know how a drug’s reported price became a selling point, speak with our whistleblower experts about the pricing and the pitch. We connect your knowledge of the transaction to the government payments and bring in drug-pricing whistleblower lawyers who understand manufacturer reporting and pharmacy reimbursement. We stay beside you as we build and pursue the case.